InSphero is a biotech company bringing more biologically relevant insights to in vitro testing of your new drugs.
InSphero – organotypic 3D cell culture models
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. InSphero’s patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight Microtissues including models derived from liver, pancreas, tumor, heart,brain, and skin. Adopted by customers around the world, InSphero’s panel of 3D InSight Microtissues display organotypic cell composition and morphology, greater longvity culture, and improved predictivity of compound efficacy and drug-induces toxicity compared to status quo 2-dimensional (monolayer) cell culture. Microtissues are delivered directly to customers, or are accessible through 3D InSight Standard Services, where InSphero scientists conduct tailored screening projects with rapid turnaround and strict confidentiality. Supported by an unrivalled portfolio of 3D-optimized culture media, assay protocols, and imaging solutions, InSphero microtissues and services help to identify promising drugs and toxic liabilities with greater predictivity at early development stages. This enables better pre-clinical decision making, saves both development cost, and shortens time to market. InSphero’s technology and know-how is now being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer. InSphero’s organotypic 3D InSight Microtissues are ideal for investigating pre-clinical safety and efficacy testing. Their phenotype remains stable over several weeks, allowing researchers to ask more complex questions and bring far greater assurance to their decisions. 3D InSight Microtissues can be used in a variety of applications (toxicity testing, DMPK, cancer research, stem cell research, disease modelling, etc…).
Founded in 2009, InSphero has been recognized for its scientific and commercial achievements with a number of national and international awards. This privately held company is headquartered in Schlieren close to Zurich (Switzerland) with subsidiaries in the United States (Brunswick, ME) and Waldshut (Germany). InSphero’s team combines many years’ experience in three dimensional microtissue research, engineering and laboratory automation and valuable know how in marketing communications and quality assurance. Management Team is composed by Jan Lichtenberg, Jens Kelm, Wolfgang Moritz, Melanie Aregger, Johannes Haugstetter, Stewart Hunt, Björn Niggemann and Randy Strube. Board of directors is composed by Jens Kelm, Jan Lichtenberg, Peter Niederhauser, Jürg Gysi and Beat Schillig.
More about InSphero : www.insphero.com